drugset / Trial / NCT05533372

MAD Study of IA-14069

NCT05533372

Phase 1 Recruiting 75 enrolled ILAb Co., Ltd.
RandomizedSequentialTriple-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of IA-14069 in healthy subjects and in patients with RA on stable dosese of MTX, with preliminary assessment of efficacy in RA patients.

Timeline

Start
2022-10-10
Primary completion
2025-11
Completion
2026-02

Drugs

EvaluationDrugModalityDoseRoute
Subject IA-14069 Unknown Oral
Subject Methotrexate Small molecule Oral

Indications